Smaller LDL particle size in women with polycystic ovary syndrome compared to controls
- PMID: 11318780
- DOI: 10.1046/j.1365-2265.2001.01245.x
Smaller LDL particle size in women with polycystic ovary syndrome compared to controls
Abstract
Objective: Women with polycystic ovary syndrome (PCOS) have an increased risk of cardiovascular disease. The contribution of lipid abnormalities to this higher risk, in particular atherogenic modifications of low density lipoprotein (LDL) such as a shift towards smaller LDL, has not been properly explored. We aimed to examine LDL size variation in relation to androgens and other risk factors in women with PCOS.
Design: Comparison of clinical and biochemical measurements in women with PCOS and women with normal ovarian function, of similar age and body mass index (BMI).
Patients: Thirty-one women with PCOS and 27 controls were studied. Patients were recruited from the outpatient endocrine clinic.
Measurements: Fasting total cholesterol, triglycerides (TG), high density lipoprotein (HDL), LDL, glucose, insulin, gonadotrophins, androgens, oestradiol, 17 OH progesterone and SHBG were measured. LDL particle diameter was calculated based on distance travelled in polyacrylamide native gels. Recumbent blood pressure was measured automatically.
Results: LDL particle size appeared to be significantly smaller in hyperandrogenic PCOS as compared to regularly cycling women (P = 0006), independent of variations in lipid levels. SHBG was the only independent predictor of LDL size in this population, with a strong correlation, which persisted after adjustment for all confounding variables.
Conclusions: Our results suggest that androgen excess and mild insulin-resistance (both responsible for lower SHBG) may have an early modifying effect on low density lipoprotein size in polycystic ovary syndrome women. The denser pattern observed in polycystic ovary syndrome women could by itself constitute a higher cardiovascular risk, even in the absence of overt dyslipidaemia, and contribute to the excess risk of cardiovascular disease reported in this syndrome.
Similar articles
-
Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters.Clin Endocrinol (Oxf). 2001 Apr;54(4):447-53. doi: 10.1046/j.1365-2265.2001.01228.x. Clin Endocrinol (Oxf). 2001. PMID: 11318779
-
A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study.J Clin Endocrinol Metab. 2008 Feb;93(2):470-6. doi: 10.1210/jc.2007-1756. Epub 2007 Dec 4. J Clin Endocrinol Metab. 2008. PMID: 18056772
-
Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.Int J Clin Pract. 2009 Jan;63(1):56-62. doi: 10.1111/j.1742-1241.2008.01897.x. Int J Clin Pract. 2009. PMID: 19125993
-
Metabolic effect of obesity on polycystic ovary syndrome in adolescents: a meta-analysis.J Obstet Gynaecol. 2017 Nov;37(8):1036-1047. doi: 10.1080/01443615.2017.1318840. Epub 2017 Jun 28. J Obstet Gynaecol. 2017. PMID: 28657375 Review.
-
Dyslipidemia in women with polycystic ovary syndrome.Obstet Gynecol Sci. 2013 May;56(3):137-42. doi: 10.5468/ogs.2013.56.3.137. Epub 2013 May 16. Obstet Gynecol Sci. 2013. PMID: 24327994 Free PMC article. Review.
Cited by
-
Plasma Lipoprotein(a) Levels in Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis.High Blood Press Cardiovasc Prev. 2023 Jul;30(4):305-317. doi: 10.1007/s40292-023-00585-2. Epub 2023 Jun 7. High Blood Press Cardiovasc Prev. 2023. PMID: 37284910 Review.
-
Evaluation of a Summary Score for Dyslipidemia, Oxidative Stress and Inflammation (the Doi Score) in Women with Polycystic Ovary Syndrome and its Relationship with Obesity.J Med Biochem. 2018 Dec 1;37(4):476-485. doi: 10.2478/jomb-2018-0008. eCollection 2018 Dec. J Med Biochem. 2018. PMID: 30584408 Free PMC article.
-
Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model.Am J Physiol Endocrinol Metab. 2019 Jan 1;316(1):E16-E33. doi: 10.1152/ajpendo.00018.2018. Epub 2018 Aug 28. Am J Physiol Endocrinol Metab. 2019. PMID: 30153063 Free PMC article.
-
Effects of orlistat on serum androgen levels among iranian obese women with polycystic ovarian syndrome.JBRA Assist Reprod. 2018 Sep 1;22(3):180-184. doi: 10.5935/1518-0557.20180033. JBRA Assist Reprod. 2018. PMID: 29757582 Free PMC article.
-
Effect of Metformin-sustained Release Therapy on Low-density Lipoprotein Size and Adiponectin in the South Indian Women with Polycystic Ovary Syndrome.Indian J Endocrinol Metab. 2017 Sep-Oct;21(5):679-683. doi: 10.4103/ijem.IJEM_154_17. Indian J Endocrinol Metab. 2017. PMID: 28989873 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous